

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

Levoflox 5mg/ml

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml of solution for infusion contains 5 mg of levofloxacin (as hemihydrate).

1 vial of 100 ml solution for infusion contains 500 mg of levofloxacin (as hemihydrate).

Excipient(s) with known effect(s): 1 ml of solution for infusion contains: 0.15 mmol (3.5 mg) sodium.

For the full list of excipients, see section 6.1

### 3. PHARMACEUTICAL FORM

Solution for infusion.

Clear greenish-yellow solution.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Levofloxacin solution for infusion is indicated in adults for the treatment of the following infections:

- Acute pyelonephritis and complicated urinary tract infections
- Chronic bacterial prostatitis

In the below-mentioned infections levofloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections:

- Community-acquired pneumonia
- Complicated skin and soft tissue infections

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

#### 4.2 Posology and method of administration

Levoflox 5mg/ml solution for infusion is administered by slow intravenous infusion once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen. Treatment with Levoflox 5mg/ml after initial use of the intravenous preparation the treatment may be completed with an appropriate oral presentation as considered appropriate for the individual patient. Given the bioequivalence of the parenteral and oral forms, the same dosage can be used.

#### **Posology**

The following dose recommendations can be given for Levoflox 5mg/ml:

**Dosage in patients with normal renal function** (creatinine clearance >50 ml/min)

| <b>Indication</b>                           | <b>Daily dose regimen<br/>(according to severity)</b> | <b>Total duration of<br/>treatment<sup>1</sup><br/>(according to severity)</b> |
|---|---|--|
| Community-acquired pneumonia                | 500 mg once or twice daily                            | 7-14 days  |
| Acute Pyelonephritis                        | 500 mg once daily                                     | 7-10 days  |
| Complicated urinary tract infections        | 500 mg once daily                                     | 7-14 days  |
| Chronic bacterial prostatitis               | 500 mg once daily                                     | 28 days  |
| Complicated skin and soft tissue infections | 500 mg once or twice daily                            | 7-14 days  |

<sup>1</sup> Treatment duration includes intravenous plus oral treatment. The time to switch from intravenous to oral treatment depends on the clinical situation but is normally 2 to 4 days.

### **Special populations**

#### **Impaired renal function** (creatinine clearance $\leq 50$ ml/min)

|   | Dose regimen              |                           |                           |
|---|---------------------------|---------------------------|---------------------------|
|   | 250 mg/24 h               | 500 mg/24 h               | 500 mg/12 h               |
| <b>Creatinine clearance</b>                                   | <i>first dose:</i> 250 mg | <i>first dose:</i> 500 mg | <i>first dose:</i> 500 mg |
| 50-20 ml/min  | <i>then:</i> 125 mg/24 h  | <i>then:</i> 250 mg/24 h  | <i>then:</i> 250 mg/12 h  |
| 19-10 ml/min  | <i>then:</i> 125 mg/48 h  | <i>then:</i> 125 mg/24 h  | <i>then:</i> 125 mg/12 h  |
| <10 ml/min<br>(including haemodialysis and CAPD) <sup>1</sup> | <i>then:</i> 125 mg/48 h  | <i>then:</i> 125 mg/24 h  | <i>then:</i> 125 mg/24 h  |

<sup>1</sup> No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

#### **Impaired liver function**

No adjustment of dose is required since levofloxacin is not metabolized to any relevant extent by the liver and is mainly excreted by the kidneys.

#### **Elderly population**

No adjustment of dosage is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 "Tendinitis and tendon rupture" and "QT interval prolongation").

#### **Paediatric population**

Levoflox 5mg/ml is contraindicated in children and growing adolescents (see section 4.3).

#### **Method of administration**

Levoflox 5mg/ml is only intended for slow intravenous infusion; it is administered once or twice daily. The infusion time must be at least 30 minutes for 250 mg or 60 minutes for 500 mg

Levoflox 5mg/ml (see section 4.4).

For incompatibilities see section 6.2.

#### **4.3 Contraindications**

Levoflox 5mg/ml must not be used:

- in patients hypersensitive to levofloxacin or any other quinolone and any of the excipients listed in section 6.1,
- in patients with epilepsy,
- in patients with history of tendon disorders related to fluoroquinolone administration,
- in children or growing adolescents,
- during pregnancy,
- in breast-feeding women.

#### **4.4 Special warnings and precautions for use**

The use of Levoflox 5mg/ml should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with Levoflox 5mg/ml should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).

Aortic aneurysm and dissection, and heart valve regurgitation/incompetence

Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones.

Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).

Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or congenital heart valve disease or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection or heart valve disease, or in presence of other risk factors or conditions predisposing

- for both aortic aneurysm and dissection and heart valve regurgitation / incompetence (e.g. connective tissue disorders such as Marfan syndrome, or Ehlers-Danlos syndrome, Turner syndrome, Behcet's disease, hypertension, rheumatoid arthritis) or additionally
- for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis or Sjogren syndrome) or additionally
- for heart valve regurgitation / incompetence (e.g. infective endocarditis)

The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.

In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.

Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.

### **Acute pancreatitis**

Acute pancreatitis may be observed in patients taking levofloxacin. Patients should be informed of the characteristic symptoms of acute pancreatitis. Patients experiencing nausea, malaise, abdominal discomfort, acute abdominal pain or vomiting should have a prompt medical evaluation. If acute pancreatitis is suspected, levofloxacin should be discontinued; if confirmed, levofloxacin should not be restarted. Caution should be exercised in patients with a history of pancreatitis (see section 4.8).

### **Risks of resistance**

Methicillin-resistant *S. aureus* are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore, levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA infections are considered inappropriate).

Resistance to fluoroquinolones of *E. coli* - the most common pathogen involved in urinary tract infections - varies. Prescribers are advised to take into account the local prevalence of resistance in *E. coli* to fluoroquinolones.

### **Infusion time**

The recommended infusion time of at least 60 minutes for 500 mg Levoflox 5mg/ml should be observed. It is known for ofloxacin that during infusion tachycardia and a temporary decrease in blood pressure may develop. In rare cases, as a consequence of a profound drop in blood pressure, circulatory collapse may occur. Should a conspicuous drop in blood pressure occur during infusion of levofloxacin (*D*-isomer of ofloxacin), the infusion must be halted immediately.

### **Sodium content**

This medicinal product contains 177 mg sodium per 50 ml, equivalent to 8.85% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

### **Prolonged, disabling and potentially irreversible serious adverse drug reactions**

Cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (including musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. There are no pharmacological treatments established to be effective treatments of the symptoms of long lasting or disabling side effects associated with fluoroquinolones. Levoflox 5mg/ml

should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice, so that symptoms can be appropriately investigated and to avoid future exposure which could potentially worsen adverse reactions.

#### ***Tendinitis and tendon rupture***

Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients receiving daily doses of 1000 mg levofloxacin in older patients, patients with renal impairment, patients with solid organ transplants, and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.

At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with levofloxacin should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur.

#### ***Clostridium difficile-associated disease***

Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of *Clostridium difficile*-associated disease (CDAD). CDAD may range in severity from mild to life-threatening, the most severe form of which is pseudo-membranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.

#### ***Patients predisposed to seizures***

Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or receiving concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.

#### ***Patients with G-6-phosphate dehydrogenase deficiency***

Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.

#### ***Patients with renal impairment***

Since levofloxacin is excreted mainly by the kidneys, the dose of Levoflox 5 mg/ml should be adjusted in patients with renal impairment (see section 4.2).

#### ***Hypersensitivity reactions***

Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.

#### ***Severe cutaneous adverse reactions***

Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN : also known as Lyell's Syndrome), Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life threatening or fatal, have been reported with levofloxacin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored. If signs and symptoms suggestive of these reactions appear, levofloxacin should be discontinued immediately and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS, TEN or DRESS with the use of levofloxacin, treatment with levofloxacin must not be restarted in this patient at any time.

### ***Disglycaemia***

As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, occurring more frequently in the elderly, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (See section 4.8).

Levofloxacin treatment should be stopped immediately if a patient reports blood glucose disturbance and alternative nonfluoroquinolone antibacterial therapy should be considered.

### ***Prevention of photosensitisation***

Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g., sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.

### ***Patients treated with Vitamin K antagonists***

Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).

### ***Psychotic reactions***

Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour - sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued immediately at the first signs or symptoms of these reactions and patients should be advised to contact their prescriber for advice. Alternative nonfluoroquinolone antibacterial therapy should be considered, and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.

### ***QT interval prolongation***

Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:

- congenital long QT syndrome
- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmic, tricyclic antidepressants, macrolides, antipsychotics)
- uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)
- cardiac disease (e.g., heart failure, myocardial infarction, bradycardia)

Elderly patients and women may be more sensitive to QTc-prolonging medications.

Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations (See sections 4.2 Elderly population, 4.5, 4.8 and 4.9).

### ***Peripheral neuropathy***

Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with Levoflox 5mg/ml should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition. (see section 4.8)

### ***Hepatobiliary disorders***

Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus or tender abdomen.

### ***Exacerbation of myasthenia gravis***

Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.

### ***Vision disorders***

If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).

### ***Superinfection***

The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.

### ***Interference with laboratory test***

In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by a more specific method. Levofloxacin may inhibit the growth of *Mycobacterium tuberculosis* and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.

## **4.5 Interaction with other medicinal products and other forms of interaction**

### **Effect of other medicinal products on Levoflox 5mg/ml**

#### ***Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs***

No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However, a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold.

Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.

#### ***Probenecid and cimetidine***

Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.

Caution should be exercised when levofloxacin is coadministered with drugs that effect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.

#### ***Other relevant information***

Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.

### **Effect of Levoflox 5mg/ml on other medicinal products**

#### ***Ciclosporin***

The half-life of ciclosporin was increased by 33% when co-administered with levofloxacin.

#### ***Vitamin K antagonists***

Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin).

Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).

#### ***Drugs known to prolong QT interval***

Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmic, tricyclic antidepressants, macrolides, antipsychotics) (See section 4.4 QT interval prolongation).

#### ***Other relevant information***

In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.

## **4.6 Fertility, pregnancy and lactation**

### ***Pregnancy***

There is a limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

However, in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin 5mg/ml must not be used in pregnant women (see sections 4.3 and 5.3).

#### **Breast-feeding**

Levofloxacin 5mg/ml is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however, other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin 5mg/ml must not be used in breast-feeding women (see sections 4.3 and 5.3).

#### **Fertility**

Levofloxacin caused no impairment of fertility or reproductive performance in rats.

#### **4.7 Effects on ability to drive and use machines**

Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

#### **4.8 Undesirable effects**

The information given below is based on data from clinical studies in more than 8300 patients and on extensive post-marketing experience.

Frequencies in this table are defined using the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$ ,  $< 1/10$ ), uncommon ( $\geq 1/1000$ ,  $< 1/100$ ), rare ( $\geq 1/10000$ ,  $< 1/1000$ ), very rare ( $< 1/10000$ ), not known (cannot be estimated from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

| <b>System organ class</b>                | <b>Common (<math>\geq 1/100</math> to <math>&lt; 1/10</math>)</b> | <b>Uncommon (<math>\geq 1/1000</math> to <math>&lt; 1/100</math>)</b> | <b>Rare (<math>\geq 1/10000</math> to <math>&lt; 1/1000</math>)</b>                         | <b>Not known (cannot be estimated from available data)</b>                            |
|--|---|---|---|---|
| Infections and infestations              |   | Fungal infection including Candida infection<br>Pathogen resistance   |   |   |
| Blood and the lymphatic system disorders |   | Leukopenia<br>Eosinophilia  | Thrombocytopenia<br>Neutropenia   | Pancytopenia<br>Agranulocytosis<br>Haemolytic anaemia                                 |
| Immune system disorders                  |   |   | Angioedema<br>Hypersensitivity (see section 4.4)  | Anaphylactic shock <sup>a</sup><br>Anaphylactoid shock <sup>a</sup> (see section 4.4) |
| Endocrine disorders                      |   |   | Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)                         |   |
| Metabolism and nutrition disorders       |   | Anorexia  | Hypoglycaemia particularly in diabetic patients,<br>Hypoglycaemic coma<br>(see section 4.4) | Hyperglycaemia<br>(see section 4.4)   |

| <b>System organ class</b>                       | <b>Common (≥1/100 to &lt;1/10 )</b> | <b>Uncommon (≥1/1000 to &lt;1/100)</b>      | <b>Rare (≥1/10000 to &lt;1/1000)</b>  | <b>Not known (cannot be estimated from available data)</b>  |
|---|-------------------------------------|---|---|---|
| Psychiatric Disorders*                          | Insomnia                            | Anxiety<br>Confusional state<br>Nervousness | Psychotic reactions (with e.g. hallucination, paranoia)<br>Depression<br>Agitation<br>Abnormal dreams<br>Nightmares, Delirium | Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)  |
| Nervous system Disorders*                       | Headache<br>Dizziness               | Somnolence<br>Tremor<br>Dysgeusia           | Convulsion (see sections 4.3 and 4.4)<br>Paraesthesia<br>Memory impairment  | Peripheral sensory neuropathy (see section 4.4)<br>Peripheral sensory motor neuropathy (see section 4.4)<br>Parosmia including anosmia<br>Dyskinesia<br>Extrapyramidal disorder<br>Ageusia<br>Syncope<br>Benign intracranial hypertension         |
| Eye disorders*                                  |                                     |   | Visual disturbances such as blurred vision (see section 4.4)  | Transient vision loss (see section 4.4)   |
| Ear and labyrinth disorders*                    |                                     | Vertigo                                     | Tinnitus  | Hearing loss<br>Hearing impaired  |
| Cardiac Disorders**                             |                                     |   | Tachycardia<br>Palpitation  | Ventricular tachycardia, which may result in cardiac arrest<br>Ventricular arrhythmia and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation), electrocardiogram QT prolonged (see sections 4.4 and 4.9) |
| Vascular Disorders**                            | Phlebitis                           |   | Hypotension   |   |
| Respiratory, thoracic and mediastinal disorders |                                     | Dyspnoea                                    |   | Bronchospasm<br>Pneumonitis allergic  |

| <b>System organ class</b>                             | <b>Common (≥1/100 to &lt;1/10 )</b>                           | <b>Uncommon (≥1/1000 to &lt;1/100)</b>                    | <b>Rare (≥1/10000 to &lt;1/1000)</b>  | <b>Not known (cannot be estimated from available data)</b>  |
|---|---|---|---|---|
| Gastrointestinal disorders                            | Diarrhoea<br>Vomiting<br>Nausea                               | Abdominal pain<br>Dyspepsia<br>Flatulence<br>Constipation |   | Diarrhoea-haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudo-membranous colitis (see section 4.4)<br>Pancreatitis (see section 4.4) |
| Hepatobiliary disorders                               | Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT) | Blood bilirubin increased                                 |   | Jaundice and severe liver injury, including fatal cases with acute liver failure, primarily in patients with severe underlying diseases (see section 4.4)<br>Hepatitis      |
| Skin and subcutaneous tissue disorders <sup>b</sup>   |   | Rash<br>Pruritus<br>Urticaria<br>Hyperhidrosis            | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (see section 4.4), Fixed drug eruption  | Toxic epidermal necrolysis<br>Stevens-Johnson syndrome<br>Erythema multiforme<br>Photosensitivity reaction (see section 4.4)<br>Leukocytoclastic vasculitis<br>Stomatitis   |
| Musculoskeletal and connective tissue disorders*      |   | Arthralgia<br>Myalgia                                     | Tendon disorders, tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon)<br>Muscular weakness which may be of special importance in patients with myasthenia gravis (see section 4.4) | Rhabdomyolysis (see sections 4.3 and 4.4)<br>Ligament rupture<br>Muscle rupture<br>Arthritis  |
| Renal and urinary disorders                           |   | Blood creatinine increased                                | Renal failure acute (e.g. due to interstitial nephritis)  |   |
| General disorders and administration site conditions* | Infusion site reaction (pain, reddening)                      | Asthenia  | Pyrexia   | Pain (including pain in back, chest, and extremities)   |

<sup>a</sup> Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose.

<sup>b</sup> Mucocutaneous reactions may sometimes occur even after the first dose.

\*

\*Cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, fatigue, psychiatric symptoms, memory impairment, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see section 4.4). A range of psychiatric symptoms may occur as part of these side effects, which may include, but are not necessarily limited to, sleep disorders, anxiety, panic attacks, confusion, or depression. There are no pharmacological treatments established to be effective treatments of the symptoms of long lasting or disabling side effects associated with fluoroquinolones. The frequency of these prolonged, disabling and potentially irreversible serious drug reactions cannot be estimated with precision using available data, but the reporting incidence from adverse drug reaction reports indicates the frequency is at minimum between 1/1,000 and 1/10,000 (corresponding to the Rare frequency category).

\*\* Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).

Other undesirable effects which have been associated with fluoroquinolone administration include: attacks of porphyria in patients with porphyria.

### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il/>.

## **4.9 Overdose**

According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdosage of Levoflox 5mg/ml are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval. CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post-marketing experience.

In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones,  
ATC code: J01MA12

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.

#### ***Mechanism of action***

As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA- gyrase complex and topoisomerase IV.

#### ***PK/PD relationship***

The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum ( $C_{max}$ ) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).

#### ***Mechanism of resistance***

Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in *Pseudomonas aeruginosa*) and efflux mechanisms may also affect susceptibility to levofloxacin.

Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.

#### ***Breakpoints***

The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/l).

EUCAST clinical MIC breakpoints for levofloxacin (version 10.0, 2020-01-01):

| <b>Pathogen</b>  | <b>Susceptible</b> | <b>Resistant</b> |
|--|--------------------|------------------|
| Enterobacteriales  | ≤0.5 mg/L          | >1 mg/L          |
| <i>Pseudomonas</i> spp.  | ≤0.001 mg/L        | >1 mg/L          |
| <i>Acinetobacter</i> spp.  | ≤0.5 mg/L          | >1 mg/L          |
| <i>Staphylococcus</i><br>spp. <i>S.aureus</i>                                    | ≤0.001 mg/L        | >1 mg/L          |
| <i>Coagulase-negative staphylococci</i>  | ≤ 0.001 mg/L       | >1 mg/L          |
| <i>S. pneumoniae</i>   | ≤0.001 mg/L        | >2 mg/L          |
| <i>Streptococcus</i> A, B, C, G  | ≤0.001 mg/L        | >2 mg/L          |
| <i>H. influenzae</i>   | ≤0.06 mg/L         | >0.06 mg/L       |
| <i>M. catarrhalis</i>  | ≤0.125 mg/L        | >0.125 mg/L      |
| <i>H.pylori</i>  | ≤1 mg/L            | >1 mg/L          |
| <i>A.sanguinicola</i> and <i>urinae</i> <sup>1</sup><br>(uncomplicated UTI only) | ≤2 mg/L            | >2 mg/L          |
| <i>K.kingae</i>  | ≤0.125 mg/L        | >0.125 mg/L      |
| Non-species related<br>breakpoints   | ≤0.5 mg/L          | >1 mg/L          |

1. Susceptibility can be inferred from ciprofloxacin susceptibility.

The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

### **Commonly susceptible species**

#### Aerobic Gram-positive bacteria

*Bacillus anthracis*  
*Staphylococcus aureus* methicillin-susceptible  
*Staphylococcus saprophyticus*  
Streptococci, group C and G  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*  
*Streptococcus pyogenes*

#### Aerobic Gram-negative bacteria

*Eikenella corrodens*  
*Haemophilus influenzae*  
*Haemophilus para-influenzae*  
*Klebsiella oxytoca*  
*Moraxella catarrhalis*  
*Pasteurella multocida*  
*Proteus vulgaris*  
*Providencia rettgeri*

#### Anaerobic bacteria

*Peptostreptococcus*

#### Other

*Chlamydophila pneumoniae*  
*Chlamydophila psittaci*  
*Chlamydia trachomatis*

*Legionella pneumophila*

*Mycoplasma pneumoniae*  
*Mycoplasma hominis*  
*Ureaplasma urealyticum*

### **Species for which acquired resistance may be a problem**

#### Aerobic Gram-positive bacteria

*Enterococcus faecalis*  
*Staphylococcus aureus* methicillin-resistant<sup>#</sup>  
Coagulase negative *Staphylococcus* spp.

#### Aerobic Gram-negative bacteria

*Acinetobacter baumannii*  
*Citrobacter freundii*  
*Enterobacter aerogenes*  
*Enterobacter agglomerans*  
*Enterobacter cloacae*  
*Escherichia coli*  
*Klebsiella pneumoniae*  
*Morganella morganii*  
*Proteus mirabilis*  
*Providencia stuartii*  
*Pseudomonas aeruginosa*  
*Serratia marcescens*

#### Anaerobic bacteria

*Bacteroides fragilis*

### **Inherently resistant strains**

#### **Aerobic Gram-positive bacteria**

*Enterococcus faecium*

<sup>#</sup> Methicillin-resistant *S. aureus* is very likely to possess co-resistance to fluoroquinolones, including levofloxacin

# Methicillin-resistant *S. aureus* are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.

## 5.2 Pharmacokinetic properties

### **Absorption**

Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2 h. The absolute bioavailability is 99-100%.

Food has little effect on the absorption of levofloxacin.

Steady-state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.

### **Distribution**

Approximately 30-40% of levofloxacin is bound to serum protein.

The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.

### **Penetration into tissues and body fluids**

Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.

### **Biotransformation**

Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for <5% of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.

### **Elimination**

Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma ( $t_{1/2}$ : 6-8 h). Excretion is primarily by the renal route (>85% of the administered dose).

The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/- 29.2 ml/min.

There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.

### **Linearity**

Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.

### **Special populations**

#### **Subjects with renal insufficiency**

The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function, renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:

#### **Pharmacokinetics in renal insufficiency following single oral 500 mg dose**

|                           |     |       |       |
|---------------------------|-----|-------|-------|
| Cl <sub>cr</sub> [ml/min] | <20 | 20-49 | 50-80 |
| Cl <sub>R</sub> [ml/min]  | 13  | 26    | 57    |
| t <sub>1/2</sub> [h]      | 35  | 27    | 9     |

#### **Elderly subjects**

There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.

#### **Gender differences**

Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.

## 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.

Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.

Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells *in vitro*. These effects can be attributed to inhibition of topoisomerase II. *In vivo* tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.

Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenity study.

In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium chloride  
Hydrochloride acid 37%  
Water for injection.

### **6.2 Incompatibilities**

In the absence of compatibility studies, Levoflox 5mg/ml solution for infusion must not be mixed with other medicinal products.

### **6.3 Shelf life**

The expiry date of the product is indicated on the packaging materials.

*Shelf life after removal of the outer packaging:* 3 days (under indoor light conditions)

For the possibility of microbial contamination, the product should be used immediately. If the medication is not used immediately, the time and storage conditions during use of the product are the responsibility of the user.

### **6.4 Special precautions for storage**

Keep the vial in the original packaging in order to protect from light (see section 6.3 "Shelf life"). Inspect visually prior to use. Only clear solutions without particles should be used.

Store below 25 °C.

### **6.5 Nature and contents of container**

100 ml, type II glass vial with chlorobutyl rubber stopper and tear-off aluminium lid. Each vial contains 100 ml solution for infusion.

Packs of 1, 5 and 25 vials.

Not all packs sizes may be marketed.

### **6.6 Special precautions for disposal and other handling**

Levoflox 5mg/ml solution for infusion should be used immediately after perforation of the rubber stopper in order to prevent any bacterial contamination. No protection from light is necessary during infusion.

This medicinal product is for single use only.

As for all medicines, any unused medicinal product should be disposed of accordingly and in compliance with local environmental regulations.

## **7 MARKETING AUTHORISATION HOLDER**

Tec-O-Pharm-Libra LTD POB 45054, Jerusalem 91450

## **8 MANUFACTURER**

Bioindustria Laboratorio Italiano Medicinali (signed Bioindustria L.I.M.) Via De Ambrosiis, 2  
Novi Ligure (AL) – Italy.

Revised in 07/2025 according to MOH's guidelines